RNK05047 / Ranok Therap - LARVOL DELTA

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) (clinicaltrials.gov) - P1/2 | N=32 | Recruiting | Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. | N=105 ➔ 32 | Trial completion date: Mar 2025 ➔ Sep 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Enrollment change • Trial completion date • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) (clinicaltrials.gov) - P1/2 | N=105 | Recruiting | Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. | Trial completion date: Oct 2024 ➔ Mar 2025 | Trial primary completion date: Feb 2024 ➔ Dec 2024

Metastases • Trial completion date • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

An updated patent review of BRD4 degraders. (PubMed, Expert Opin Ther Pat) - "Excitingly, RNK05047 is now in phase I/II clinical trials, indicating that selective BRD4 protein degradation may offer a viable therapeutic strategy, particularly for cancer. Targeting BRD4 with small molecule BRD4 degraders provides a promising approach with the potential to overcome therapeutic resistance for treating various BRD4-associated diseases."

Journal • Review • Infectious Disease • Oncology • Targeted Protein Degradation • BRD4

Ranok Therapeutics Expands Clinical Testing of CHAMP BRD4 Protein Degrader RNK05047 to China (Businesswire) - "Ranok Therapeutics...announced the initiation of patient dosing in China for a Phase 1 study of RNK05047, its first protein degrader candidate. The study, which mirrors an ongoing Phase 1 study in the U.S., will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RNK05047 in Chinese patients with advanced solid tumors or lymphomas. Ranok anticipates preliminary data from both the US and China Phase 1 studies by the end of 2024."

P1 data • Trial status • Lymphoma • Solid Tumor

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) (clinicaltrials.gov) - P1/2 | N=105 | Recruiting | Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd.

Metastases • Trial completion date • Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Tumor-selective, chaperone-mediated protein degradation (CHAMP) of the bromodomain transcription factor BRD4 (AACR-NCI-EORTC 2022) - "Based on these findings, we have initiated a Phase 1/2 clinical of the BRD4-CHAMP compound RNK05047 in solid tumors and lymphoma patients."

Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • BRD2 • BRD3 • BRD4 • HSP90AA1

Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP Protein Degrader (Businesswire) - "Ranok Therapeutics...announced the initiation of patient dosing in the U.S. for a Phase 1/2 study of RNK05047. The trial, entitled CHAMP-1, will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RNK05047 in patients with advanced solid tumors or diffuse large B-cell lymphoma (DLBCL). Ranok anticipates preliminary data from the study in the second half of 2023."

P1/2 data • Trial status • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P1/2 | N=105 | Recruiting | Sponsor: Ranok Therapuetics Co. Ltd.

New P1/2 trial • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Ranok Therapeutics Announces U.S. FDA Clearance to Proceed With Its First-in-Human Trial of RNK05047 in Patients With Advanced Solid Tumor Cancers and Lymphomas (CHAMP-1) (Businesswire) - "Ranok Therapeutics...announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for RNK05047, a novel treatment for patients with advanced solid tumors and lymphomas. Ranok expects to begin enrollment of the Phase 1/2 study entitled CHAMP-1 in the first half of 2022."

IND • New P1/2 trial • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor